The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 11, 2022
Filed:
May. 22, 2017
Applicant:
Emory University, Atlanta, GA (US);
Inventors:
Edmund K. Waller, Atlanta, GA (US);
Jian-Ming Li, Atlanta, GA (US);
Mohammad S. Hossain, Lilburn, GA (US);
Assignee:
Emory University, Atlanta, GA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61P 35/02 (2006.01); A61K 38/22 (2006.01); C07K 14/575 (2006.01); A61K 38/16 (2006.01); C12N 5/071 (2010.01); A61K 39/395 (2006.01); C12N 5/0789 (2010.01); C12N 5/0775 (2010.01); C12N 5/078 (2010.01); A61K 35/14 (2015.01); A61K 35/17 (2015.01); A61K 38/04 (2006.01); A61K 39/245 (2006.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 35/14 (2013.01); A61K 35/17 (2013.01); A61K 38/04 (2013.01); A61K 38/16 (2013.01); A61K 38/2278 (2013.01); A61K 39/245 (2013.01); A61P 35/02 (2018.01); C12N 5/0634 (2013.01); C12N 5/0647 (2013.01); C12N 5/0662 (2013.01); Y02A 50/30 (2018.01);
Abstract
Inhibition of the VIP signaling pathway with VIP antagonist is contemplated. In certain embodiments, the disclosure relates to methods of enhancing the immune response to a cell therapy comprising administering a VIP antagonist to a subject in combination with a cell. In certain embodiments, the subject is diagnosed with leukemia or lymphoma. In certain embodiments, the cell is a blood cell, bone marrow cell, leukocyte, T-cell, natural killer cell, a hematopoietic stem cell, a G-CSF mobilized or non-mobilized blood mononuclear cell.